Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 05, 2023 1:53pm
148 Views
Post# 35527661

Interesting day of trading

Interesting day of tradingSo we open up at $2.05 and CIBC quicklyknocks it down to $2 but suddenly Anonymous shows up on scene and starts buying aggressively here driving us up to $2.14, thats a big swing. CIBC is hanging inbthere firing bullets on the sell side. We have a Mexican stand off here. I cant see the  shorts winning in the long run. The science is just too good, risk of side effects dimished, in fact higher doses are tolerated in humans with successful higher dose study which in fact should improve results. No threat of dilution as we have $5M from Canadian government and recent FDA phase 2 clinical trial for AKI. The stars are aligning here and you cant keep a good horse down. This should be trading at $15 today so $2.14 is a screaming buy. This will be a $75 a - $100 stock in tge future. We have zero competition in our field. I think big pharma has us on their radar screen with bags of cash to spend!!
<< Previous
Bullboard Posts
Next >>